country

Change Language

EN - English
FR - Français
DE - Deutsch
ES - Español
JA - 日本語
KO - 한국어

Country or Region:

United States

Product Name	Size / Unit Price	Qty

Total: USD 0.00 Checkout

Art. -Nr.: HY-P992534

Copy Link Print Information

LEVI-04

LEVI-04 is a p75NTR-Fc fusion protein. LEVI-04 blocks and clears neurotrophins, binding excess NGF to block NGF activity, and binds NT-3 with high affinity to inhibit NT-3 activity. LEVI-04 inhibits NT-3-mediated TrkC receptor signaling and supplements endogenous p75NTR. LEVI-04 can be used in research on osteoarthritis and knee osteoarthritis.

Nur für Forschungszwecke. Wir verkaufen nicht an Patienten.

Speicherung:

Please store the product under the recommended conditions in the Certificate of Analysis.

LEVI-04 Chemical Structure

Größe

Preis

Verfügbarkeit

Menge

Amount: USD 0.00

* Bitte wählen Sie Menge, bevor Sie Artikel hinzufügen.

Use of MCE Products

Strong Fluorescence Signal / Multi-Disciplinary Applications / High Fluorescence Specificity

Biologische Aktivität
- Beschreibung
- Species Reactivity
- IC₅₀ & Target
- Target
- Conjugated
- Anwendung
Chemical Information
Reinheit & Dokumentation
Verweise
Calculators
Help & FAQs
Classifications
Bioz

Biologische Aktivität

Beschreibung

Species Reactivity

Human

IC₅₀ & Target

^[1]

TrkC

Alle Trk Receptor Isoform-spezifische Produkte anzeigen :

Target

NT-3

Conjugated

Unconjugated

Anwendung

ELISA, FACS, Functional assay

Chemical Information

SMILES

[LEVI-04]
Speicherung

Please store the product under the recommended conditions in the Certificate of Analysis.

Reinheit & Dokumentation

Inhibitory Antibodies User Guide (603 KB)

Verweise

[1]. Fedotcheva TA, et al. Current State of the Neurotrophin-Based Pharmaceutics in the Treatment of Neurodegenerative Diseases and Neuroinflammation. Medical sciences (Basel, Switzerland). 2025 Dec 29;14(1):15. [Content Brief]

[2]. Conaghan P G, et al. OA04 A randomised controlled Phase II trial of LEVI-04, a novel neurotrophin-3 inhibitor, in knee osteoarthritis demonstrates substantially improved pain and function without deleterious effects on joint structure[J]. Rheumatology, 2025, 64(Supplement_3): keaf142. 004.

[3]. Conaghan P G, et al. LEVI-04, A NOVEL NEUROTROPHIN-3 INHIBITOR, SUBSTANTIALLY IMPROVES PAIN AND FUNCTION IN PEOPLE WITH KNEE OSTEOARTHRITIS: A RANDOMISED CONTROLLED PHASE II TRIAL[J]. Osteoarthritis and Cartilage, 2025, 33: S65-S66.

Calculators

Molaritätsrechner

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Mass Mass

Konzentration Konzentration

Volumen Volumen

Molecular Weight Molecular Weight

Verdünnungsrechner

Konzentration _{(Stammlösung)} × Volumen _{(Stammlösung)} = Konzentration _{(Ziellösung)} × Volumen _{(Ziellösung)}

Konzentration _{(Stammlösung)} Konzentration _{(Stammlösung)}

Volumen _{(Stammlösung)} Volumen _{(Stammlösung)}

Konzentration _{(Ziellösung)} Konzentration _{(Ziellösung)}

Volumen _{(Ziellösung)} Volumen _{(Ziellösung)}

Help & FAQs

How should lyophilized recombinant proteins be reconstituted and stored?

1. Before opening the cap, centrifuge the vial at 13000 rpm for 20-30 seconds. This step will ensure that any lyophilized powder that may have adhered to the cap or walls is collected at the bottom of the vial, minimizing the risk of product loss.

Bioz

Keywords

MOQ

Minimum order quantity

100 mg

Angebot einholen Auf Lager

Other size

Angebot einholen